Physician profile
Barry M Garner
NPI 1306832811
$7,844.13
in general payments reported to CMS, 2019-2025
27 companies · $4,066 in 2025
The $4,066 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $330 · 2021: $308 · 2022: $986 · 2023: $776 · 2024: $707 · 2025: $4,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $2,236 · Travel and Lodging: $299 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $2,236.25 |
| Travel and Lodging | $299.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $3,544.34 | 2025 | |
| Abbvie INC. | $1,595.75 | 2019-2025 | |
| Janssen Biotech, INC. | $495.54 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.81 | 2019-2024 | Xifaxan, Plenvu |
| Pfizer INC. | $360.65 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $177.37 | 2022-2024 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $146.94 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $138.21 | 2019-2020 | |
| Braintree Laboratories, INC. | $124.01 | 2019 | |
| Amgen INC. | $115.41 | 2022 | |
| Aimmune Therapeutics, INC. | $90.61 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $90.22 | 2025 | Tremfya, Remicade, Stelara |
| Celgene Corporation | $89.12 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $59.68 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $58.31 | 2021-2023 | Linzess |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.27 | 2021-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $43.29 | 2022 | |
| Boston Scientific Corporation | $39.14 | 2023-2025 | Spyglass, Spyglass Discover |
| Evoke Pharma, INC. | $36.19 | 2022-2023 | Gimoti |
| Novo Nordisk INC | $33.72 | 2021-2025 | Wegovy |
| Genzyme Corporation | $28.75 | 2023 | |
| Olympus America INC. | $28.02 | 2020-2022 | |
| Mauna Kea Technologies, INC. | $24.35 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.37 | 2025 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $17.93 | 2024 | Hemostasis Clips |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $10.83 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.